Marie-Noelle Lavaut
Overview
Explore the profile of Marie-Noelle Lavaut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bressy C, Lac S, Nigri J, Leca J, Roques J, Lavaut M, et al.
Cancer Res
. 2017 Dec;
78(4):909-921.
PMID: 29269518
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive stroma and pathogenic modifications to the peripheral nervous system that elevate metastatic capacity. In this study, we show that the IL6-related stem...
2.
Olivares O, Mayers J, Gouirand V, Torrence M, Gicquel T, Borge L, et al.
Nat Commun
. 2017 Jul;
8:16031.
PMID: 28685754
Tissue architecture contributes to pancreatic ductal adenocarcinoma (PDAC) phenotypes. Cancer cells within PDAC form gland-like structures embedded in a collagen-rich meshwork where nutrients and oxygen are scarce. Altered metabolism is...
3.
Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, et al.
J Clin Invest
. 2016 Oct;
126(11):4140-4156.
PMID: 27701147
The intratumoral microenvironment, or stroma, is of major importance in the pathobiology of pancreatic ductal adenocarcinoma (PDA), and specific conditions in the stroma may promote increased cancer aggressiveness. We hypothesized...
4.
Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, et al.
Proc Natl Acad Sci U S A
. 2015 Feb;
112(8):2473-8.
PMID: 25675507
The malignant progression of pancreatic ductal adenocarcinoma (PDAC) is accompanied by a profound desmoplasia, which forces proliferating tumor cells to metabolically adapt to this new microenvironment. We established the PDAC...
5.
Chabas J, Stephan D, Marqueste T, Garcia S, Lavaut M, Nguyen C, et al.
PLoS One
. 2013 Jun;
8(5):e65034.
PMID: 23741446
Previously, we demonstrated i) that ergocalciferol (vitamin D2) increases axon diameter and potentiates nerve regeneration in a rat model of transected peripheral nerve and ii) that cholecalciferol (vitamin D3) improves...
6.
Guillaumond F, Leca J, Olivares O, Lavaut M, Vidal N, Berthezene P, et al.
Proc Natl Acad Sci U S A
. 2013 Feb;
110(10):3919-24.
PMID: 23407165
Pancreatic ductal adenocarcinoma is one of the most intractable and fatal cancer. The decreased blood vessel density displayed by this tumor not only favors its resistance to chemotherapy but also...
7.
Charpin C, Tavassoli F, Secq V, Giusiano S, Villeret J, Garcia S, et al.
Int J Cancer
. 2011 Nov;
131(3):E236-43.
PMID: 22120430
We recently reported that standardized quantitative immunohistochemical (IHC) assays allowed prediction of an adverse outcome among 572 node negative (N-) patients with breast carcinoma (BrCa). To further validate our prior...
8.
Taranger-Charpin C, Giusiano S, Secq V, Djemli A, Andrac L, Lavaut M, et al.
Bull Acad Natl Med
. 2010 Jul;
193(9):2045-60.
PMID: 20666017
We examined a series of 667 patients with node-negative breast carcinomas in order to identify prognostic immunohistochemical molecular signatures for the prediction of early metastasis, and potential new therapeutic targets....
9.
Giusiano S, Secq V, Carcopino X, Carpentier S, Andrac L, Lavaut M, et al.
Int J Oncol
. 2010 Mar;
36(4):889-98.
PMID: 20198333
The aim of this study was to identify a prognostic immunohistochemical signature indicative of risk of early metastasis in node-negative breast carcinomas that would also be relevant to the development...
10.
Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut M, et al.
Int J Oncol
. 2009 Mar;
34(4):983-93.
PMID: 19287955
We aimed in this study at identifying prognostic immunohistochemical molecular signatures indicative of disease outcome, also relevant for development of new specific therapies, in triple-negative (ER, PR, c-erbB2- negative) breast...